Intra-Cellular Therapies to Present at the Cowen and Company 37th Annual Health Care Conference
February 28 2017 - 8:00AM
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical
company focused on the development of therapeutics for central
nervous system ("CNS") disorders, today announced that Sharon
Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to
present at the Cowen and Company 37th Annual Health Care Conference
in Boston, MA. The presentation is scheduled for Tuesday, March 7,
2017 at 9:20 am EST.
The live and archived webcast can be accessed under "Events
& Presentations" in the Investor Relations section of the
Company's website at www.intracellulartherapies.com. Please
log in approximately 5-10 minutes prior to the event to register
and to download and install any necessary software.
About Intra-Cellular TherapiesIntra-Cellular
Therapies is developing novel drugs for the treatment of
neuropsychiatric and neurodegenerative diseases and diseases of the
elderly, including Parkinson's and Alzheimer's disease. The Company
is developing its lead drug candidate, lumateperone, for the
treatment of schizophrenia, bipolar disorder, behavioral
disturbances in patients with dementia, including Alzheimer's
disease, depression and other neuropsychiatric and neurological
disorders. Lumateperone, a first-in-class molecule, is in Phase 3
clinical development for the treatment of schizophrenia, bipolar
depression and agitation associated with dementia, including
Alzheimer's disease. The Company is also utilizing its
phosphodiesterase platform and other proprietary chemistry
platforms to develop drugs for the treatment of CNS and other
disorders.
CONTACT:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333
Burns McClellan, Inc.
Lisa Burns
Justin Jackson (Media)
jjackson@burnsmc.com
212-213-0006
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2024 to May 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From May 2023 to May 2024